Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap

Jan 25 2018

• By Derrick Gingery

FDA entrance sign 2016

Related Content

US FDA Drug Office Reform: 'Everything' Is On The Table

Nov 15 2017

US FDA's Patient Affairs Office Is An Office … In Spirit

Nov 17 2017

Gottlieb's Complex Generics Remarks Could Signal (Some) Increased Flexibility

Nov 29 2017

Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

Nov 30 2017

Gottlieb Issues Statement On Adverse Event Limitations – An Attempt To Quell Fears?

Oct 03 2017

Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication

Oct 03 2017

Real World Evidence Benefits, Limits Explored In US FDA Demonstrations

Oct 30 2017

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

Oct 26 2017

Opioid Hearing: Senators Want Speed, But Agency Heads Stress Time, Effort

Oct 05 2017

US FDA Doesn't Support Creating Ultra-Orphan Designation

Dec 20 2017

US FDA Outlines Streamlined Development Path For Targeted Therapies

Dec 16 2017

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

Dec 12 2017

FDA's Opioid Programs: After Training, What's The Next Step?

Oct 05 2017

Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

Sep 14 2017

US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security

Aug 14 2017

Abuse Deterrent Opioids: Which Studies Will Show Real World Effect?

Jul 20 2017

US FDA May Create Immunology, Neuroscience Centers Of Excellence

Dec 02 2017

Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol

Dec 02 2017

Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price

Dec 13 2017

Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning

Dec 04 2017

'Progressive Approval' Coming? US FDA Considers Accelerated Approval Without Surrogates

Dec 01 2017

Labeling Updates For Old Drugs Could Be Faster Under Streamlining Proposal

Nov 28 2017

Gene Therapies: Safety, CMC Draft Guidances Coming From US FDA In 2018

Jan 24 2018

FDA Commissioner Outlines Priorities For Tightening Oversight Of Drug Compounding Facilities

Jan 19 2018

'Patient Experience Data' Section Added To US FDA Drug Reviews

Jan 09 2018

Disease-Specific Drug Development Guidances Coming From US FDA In 2018

Jan 19 2018

Off-Label Communications Bill Allowing Discussion Of Unapproved Drugs Advances

Jan 18 2018

In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?

Jan 11 2018

CBER Director Marks: Regenerative Medicine Enforcement Will Be 'Notched Up' In 2018

Jan 18 2018

RMAT Designation, Gene Therapies Highlight 2017 CBER Transformation

Jan 18 2018

Clinical Study Disclosures Will Make Drug Reviews More Efficient – Gottlieb

Jan 18 2018

US FDA Creates Expedited Review For Military-Related Products

Jan 16 2018

2018 An Inflection Point For mHealth After An Active Year

Jan 08 2018

FDA Biosimilar Education Campaign Will Need To Be Targeted

Sep 17 2015

FDA Making A Generic Case For Continuous Manufacturing

May 02 2016

Related Companies

Viatris Inc.

GSK plc

Additional Topics

United States FDA Review Pathway Policy Biosimilars Generic Drugs BioPharmaceutical

More from Policy & Regulation

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window